Clinical diagnosis of von Hippel-Lindau (VHL)
The clinical diagnosis of von Hippel-Lindau (VHL) disease is established in [Lonser et al 2003, Butman et al 2008, Maher et al 2011]:
A simplex case (i.e., an individual with no known family history of VHL disease) presenting with two or more characteristic lesions:
An individual with a positive family history of VHL disease in whom one or more of the following disease manifestations is present:
Note: other lesions characteristic of VHL are ELST and pancreatic neuroendocrine tumours; however these are not typically used to make a clinical diagnosis of VHL.
Retinal haemangioblastomas are commonly referred to as retinal angiomas.
Gene Reviews accessed 23/05/2018.
Transferred to new eviQ website.
Previous website ID: 280
VHL protocols (ID 397 and IF 615) reviewed at the May 2018 Reference Committee meeting and this document finalised over email.
The format of the document was updated for readability
Version number updated to 3.
von Hippel-Lindau disease is a heritable multisystem cancer syndrome that is associated with a germline mutation of the VHL tumour suppressor gene on the short arm of chromosome 3. This disorder is not rare (about one in 36000 livebirths) and is inherited as a highly penetrant autosomal dominant trait (ie, with a high individual risk of disease). Affected individuals are at risk of developing various benign and malignant tumours of the central nervous system, kidneys, adrenal glands, pancreas, and reproductive adnexal organs. Because of the complexities associated with management of the various types of tumours in this disease, treatment is multidisciplinary. We present an overview of the clinical aspects, management, and treatment options for von Hippel-Lindau disease.
Von Hippel-Lindau disease (VHL) is an autosomal-dominant neoplasia syndrome that is the result of a germline mutation of the VHL tumor suppressor gene on the short arm of chromosome 3. Patients with VHL are predisposed to develop lesions of the central nervous system and viscera. Central nervous system lesions include hemangioblastomas (the most common tumor in VHL) and endolymphatic sac tumors (ELSTs). Visceral manifestations include renal carcinomas and cysts, pancreatic neuroendocrine tumors and cysts, pheochromocytomas, and cystadenomas of the reproductive adnexal organs. Despite their benign pathology, hemangioblastomas and ELSTs are a frequent cause of morbidity and mortality in patients with VHL. Recent molecular biologic investigations into these VHL-associated central nervous system lesions provide new insight into their origin and development. Emerging data from serial imaging and clinical surveillance protocols provide insight into the natural history of these lesions. Because of the dissimilar pathobiology and clinical course between hemangioblastomas and ELSTs, the optimal management strategies for these neurologic manifestations of VHL are very different.
The autosomal dominantly inherited disorder von Hippel-Lindau disease (VHL) is caused by germline mutations in the VHL tumour suppressor gene (TSG). VHL mutations predispose to the development of a variety of tumours (most commonly retinal and central nervous system haemangioblastomas, clear cell renal carcinoma and phaeochromocytomas). Here, we review the clinical and genetic features of VHL disease, briefly review the molecular pathogenesis and outline clinical management and tumour surveillance strategies.
Send feedback for this page
The currency of this information is guaranteed only up until the date of printing, for any updates please check:
https://www.eviq.org.au/p/3162
01 Mar 2021
Title